BIMEKIZUMAB MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Bimekizumab Market Size and Forecast – 2025 to 2032

The Global Bimekizumab Market is estimated to be valued at USD 1.52 Bn in 2025 and is expected to reach USD 5.61 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 20.5% from 2025 to 2032. This substantial growth reflects increasing adoption and expanded applications of bimekizumab across various therapeutic areas, supported by ongoing clinical advancements and favorable regulatory approvals.

Key Takeaways of the Global Bimekizumab Market

• Plaque psoriasis segment is expected to lead the global bimekizumab market, accounting for 54.3% share in 2025.
• Adult segment is estimated to capture 65.7% of the bimekizumab market share in 2025.
• Male segment is projected to dominate by gender, holding a 56.7% of the market share in 2025.
• North America is expected to lead the market, holding a share of 39.5% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with 23.5% share in 2025.

Market Overview

• Market trends show rising demand for targeted immunotherapies across autoimmune diseases.
• Bimekizumab is gaining traction due to dual IL-17A and IL-17F inhibition and improved clinical efficacy.
• Growing investments in biologics and strategic partnerships are accelerating market expansion.
• Increasing awareness and focus on personalized medicine will further drive bimekizumab uptake.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Why does Plaque Psoriasis Dominates the Global Bimekizumab Market in 2025?

The plaque psoriasis is expected to hold 54.3% of the market share in 2025, because the disease is highly prevalent and chronic. Psoriasis is a type of skin disease that is among the most common and affects the skin by producing red, scaly, and raised patches which lead to a great reduction in the quality of life for the patients. The rising incidence of autoimmune and inflammatory skin diseases globally has driven the need for advanced treatments that are both efficacious and safe compared to the traditional ones.

Inhibiting the IL-17A and IL-17F cytokines, by bimekizumab, the drug targets the main inflammatory pathways that cause plaque psoriasis. The mechanism in that manner has been credited with better and faster skin clearing results, so bimekizumab becomes a drug of choice in the mid- to severe cases where first-line therapies do not succeed.

For instance, in December 2022, the World Psoriasis Day Consortium, a global advocacy organization, highlighted psoriasis prevalence supporting the need for therapies like bimekizumab. It reported 125 million people worldwide live with psoriasis, including over 8 million patients in the U.S. Nearly 30 percent of psoriasis patients develop psoriatic arthritis, increasing demand for advanced biologics such as bimekizumab.

Source: https://www.psoriasis.org/psoriasis-statistics/

Why does the Adult Segment Dominate the Global Bimekizumab Market?

The adult category is expected to occupy the largest portion of the global bimekizumab market with 65.7% share in 2025, due to the age range of the patients for bimekizumab and the overall situation in that group regarding treatment. The adult population is the main one suffering from the conditions mentioned above, including psoriasis, psoriatic arthritis, and axial spondyloarthritis, which usually have their peak at mid-adulthood. Thus, the treatment demand is naturally increased by the higher prevalence of these diseases among adults.

Adults are, as a rule, more active in the labor market and in social life, which makes preventing and managing disease and maintaining quality of life top priorities. So, the adults are in need of quicker-acting and more efficient therapies that relieve their symptoms and improve their functioning, which is exactly what bimekizumab is doing through its strong anti-inflammatory action.

Male Segment Dominates the Global Bimekizumab Market

The male segment is projected to dominate with a 56.7% share in 2025, due to the gender-based stratification of the epidemiology of the diseases and the way the diseases are manifested differently. Several autoimmune diseases treated with bimekizumab, such as arthritis psoriatica and spondyloarthritis, are more commonly found in men than women and are even more aggressively progressing in male patients.

The demand for bimekizumab, which hits the main inflammatory pathways with its fast-acting and powerful treatment characteristics, is further encouraged by the fact that men often show more intense symptoms and earlier onset of diseases like axial spondyloarthritis, etc. Not only that, but they are also more susceptible to the increasing number of diseases related to Bimekizumab, which calls for more comprehensive treatment options that are only provided by biologic agents.

Reimbursement Landscape and Access Dynamics for Bimekizumab

• The reimbursement landscape for bimekizumab is defined by its status as a premium biologic used in chronic inflammatory diseases such as plaque psoriasis and psoriatic arthritis. In developed markets, reimbursement is available through public and private payers but is restricted by prior authorization, step-therapy, and mandatory failure of lower-cost biologics. Payers justify coverage mainly on bimekizumab’s dual IL-17A/F inhibition and superior skin clearance outcomes versus existing IL-17 agents.
• In emerging markets, reimbursement is limited and adoption is driven largely by private insurance or out-of-pocket spending, constraining patient access. Future reimbursement expansion will depend on real-world evidence showing durable outcomes, reduced treatment switching, and overall cost savings, rather than clinical efficacy alone. In December 2022, UCB, a global biopharmaceutical company, announced U.S. FDA acceptance of its BLA resubmission for bimekizumab. The U.S. FDA assigned a Class 2 review with a six-month timeline and expected action in Q2 2023.

(Source:https://www.ucb-usa.com/stories-media/UCB-U-S-News/detail/article/ucb-announces-fda-acceptance-of-bla-resubmission-for-bimekizumab)

Regional Insights

To learn more about this report, Download Free Sample

North America Bimekizumab Market Analysis and Trends

The North America region is projected to lead the market with a 39.5% share in 2025, due to the strong healthcare infrastructure, large R&D investments, and the high awareness of people's biologic therapies. Moreover, the presence of major pharmaceutical companies like UCB Pharma and Eli Lilly that have been leading the development and marketing of bimekizumab and thus contributing to the reinforcing of the region’s strong market position is another factor that accounts for North America being the leader in the market.

The developed healthcare system, together with widespread clinical trial activity and well-developed reimbursement avenues, allows for the rapid acceptance of cutting-edge treatments. Not to mention, the strong networking between academia and industry facilitates the process of bringing forth new ideas and penetrating the market that much easier; thus, it allows North America to maintain its dominant position in the bimekizumab market.

Asia Pacific Bimekizumab Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth in the market contributing 23.5% share in 2025. This growth will be driven by increasing health care costs, more patients and better understanding of autoimmune diseases. The rapid growth of cities and the better availability of health care in China, India and Japan will be the main factors contributing to the bimekizumab market.

The presence of global pharmaceutical companies and the local biopharma companies reaching the market for the first time will be the main factors driving innovations and competitive pricing strategies. Winning the war on the markets will be through clinical trials, and the made-up partnerships with global industry leaders will be the power behind the explosive growth in Asia Pacific.

Global Bimekizumab Market Outlook for Key Countries:

U.S. Bimekizumab Market Trends

The U.S. market maintains its dominant role owing to early regulatory approvals and widespread adoption of bimekizumab for indications including psoriasis, psoriatic arthritis, and other inflammatory diseases.

UCB Pharma and Eli Lilly, the top among the industry players, have been quite active in the commercial operations, and have also been putting in place extensive marketing and education programs aimed at healthcare providers. The patients have been able to access expensive biologics thanks to the well-established insurance and reimbursement policies. In addition, clinical research in the top medical centers is continually sustaining pipeline development and expanding the range of the approved indications, which makes the U.S. market very dynamic and competitive.

Germany Bimekizumab Market Trends

Germany now tops as the leading country in the European market for bimekizumab with a great deal of help from domestic and multinational companies. The strict health care reimbursement policies of the country along with the structured evaluation processes employed by the Institute for Quality and Efficiency in Health Care (IQWiG) lead to the availability of cost-effective and clinically proven treatments such as bimekizumab.

Strong pharmaceutical manufacturing capabilities and significant investments in biotechnology underpin market growth. Key players actively engage with healthcare stakeholders and patient advocacy groups to promote awareness and optimize biologic therapy usage in dermatology and rheumatology.

China Bimekizumab Market Trends

The bimekizumab market in China is seeing a quick growth spurt which is spearheaded by the government reforms that are aimed at the healthcare modernization and the biopharmaceuticals innovation. One of the measures is the inclusion of biologic drugs in the national insurance programs that facilitate patient access to and affordability of the drugs.

Roche, Eli Lilly, and other foreign companies have formed partnerships with local firms to help them in dealing with the regulations and enlarging their market. The vast clinical trials that are performed in the country utilize the large patient populations to give support to the accelerated drug approvals.

Japan Bimekizumab Market Trends

A very well-developed and tightly controlled market is what Japan is exhibiting, in addition to a high prevalence of autoimmune diseases that are the reasons for demand for new biologic treatments. The Pharmaceuticals and Medical Devices Agency (PMDA) provides very fast tracks for drug evaluation and approval, thus supporting the quick introduction of bimekizumab.

Besides, the strong research institutions not only contribute to the ongoing clinical trials but also deepen the understanding of the therapeutic potential of bimekizumab in various indications.  Bimekizumab, a monoclonal antibody targeting interleukin-17A and interleukin-17F, offers promising efficacy in managing these conditions by addressing the underlying inflammatory pathways more comprehensively than earlier therapies.

Biosimilar Threat & Patent Cliff Risk Assessment – Bimekizumab

• Patent Protection Window: Core composition and method-of-use patents provide near-term exclusivity, limiting immediate biosimilar entry.
• Patent Cliff Timing: Risk increases post key patent expiries, opening the market to biosimilar development in major regions.
• Biosimilar Development Complexity: Dual IL-17A/F targeting and complex manufacturing raise technical and regulatory barriers.
• Pricing Pressure: Post-exclusivity, biosimilars are expected to drive price erosion and tighter payer negotiations.
• Market Defense Levers: Lifecycle management, new indications, and real-world evidence will be critical to delay share loss.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In January 2025, UCB, a global biopharmaceutical company, launched high-dose bimekizumab Bimzelx in the U.S. The 320 mg single-injection syringe and autoinjector followed U.S. FDA approval in October 2024. Bimekizumab recently gained USFDA approvals for hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis indications. In May 2025, Australia’s PBAC will review PBS listing for bimekizumab in hidradenitis suppurativa.
• In May 2023, UCB a Belgium based biopharmaceutical company presented new bimekizumab data at EULAR. The data showed sustained joint and skin responses in psoriatic arthritis patients through 52 weeks. Across axial spondyloarthritis, bimekizumab reduced spinal and sacroiliac inflammation with durable benefits. Results came from Phase 3 BE COMPLETE BE MOBILE 1 and BE MOBILE 2 studies. Safety remained consistent with manageable infections and no new concerns reported.

Market Report Scope

Bimekizumab Market Report Coverage

Bimekizumab Market Dynamics

To learn more about this report, Download Free Sample

Bimekizumab Market Driver - Rising Prevalence of Psoriasis Psoriatic Arthritis and Axial Spondyloarthritis

The rising occurrence of such chronic inflammatory conditions as psoriasis, psoriatic arthritis, and axial spondyloarthritis greatly increases the demand for novel therapies like Bimekizumab. Autoimmunity is the prime cause for these diseases, which manifests in the form of persistent inflammation and immune dysfunction. Consequently, patients suffer a lot and their quality of life is substantially reduced. The situation that the world population is aging, and the environmental and genetic factors are contributing to a higher prevalence, the need for effective, targeted biologic treatments becomes more pressing.

In October 2025, UCB, a global biopharmaceutical company, highlighted disease prevalence supporting bimekizumab demand. Psoriatic arthritis affects around 0.02 to 0.25 percent of the global population. Axial spondyloarthritis prevalence ranges between 0.3 and 1.4 percent of adults worldwide. Early onset and chronic progression increase long-term need for biologics like bimekizumab.

(Source: UCB)

Bimekizumab Market Opportunity - New Indication Expansion and Lifecycle Management in Additional Inflammatory Diseases

The worldwide bimekizumab market is not only the current one but also the future big one and the key cause behind that is the expansion of its indications and continuous regulatory management which is going to reach a huge variety of inflammatory diseases beyond its already approved usages. Bimekizumab, which is a two-way blocker of interleukin-17A and interleukin-17F, is showing great potential for other chronic inflammatory and autoimmune disorders after giving wonderful results in the cases of plaque psoriasis and psoriatic arthritis. With the inclusion of ankylosing spondylitis, hidradenitis suppurativa, and inflammatory bowel disease, the patient group will be substantially increased which will result in driving the market through the already expanded clinical trials and regulatory approvals. One of the main techniques of lifecycle management is including new formulations, combination treatments, and better delivery systems which are predicted to not only improve the results but also maintain the patient’s adherence hence build up the market.

For example, Eli Lilly and Company, a global biopharmaceutical company, expanded Taltz beyond plaque psoriasis into psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis. This multi-indication strategy significantly increased patient reach and sustained long-term revenue growth. It demonstrates how expanding inflammatory disease labels can scale biologic market penetration.

Analyst Opinion (Expert Opinion)

• The bimekizumab market is growing consistently as doctors are giving more and more priority to treatments that can quickly and durably control the disease in chronic inflammatory disorders. The dual inhibition of IL-17A and IL-17F made it stand out in psoriasis and similar cases which was backed up by approvals from the most advanced regulatory authorities in major markets. The slowest thing that would happen is if there would be a combination of label expansions and continuous collection of real-world evidence to support the growth, however, they would not last long as the pressure from the new biologics and oral immune modulators competition on prices and adoption decisions is continuously on the market.
• One of the major ways through which the market has gained visibility is obtaining significant access to clinical data sharing in major audiences like the EADV Congress, AAD Annual Meeting, and EULAR Congress, where clinical outcomes and long-term safety data are being actively disseminated. UCB’s real-world studies and patient registries across Europe are already shaping treatment guidelines, while evolving reimbursement policies in key regions are improving access. Together, these developments position bimekizumab as a strong contender in the evolving immunology treatment landscape.

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Axial Spondyloarthritis
  • Non-radiographic axial spondyloarthritis (nraxSpA)
  • Other Investigational Autoimmune Indications
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Geriatric
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Dermatology Clinics
  • Rheumatology Clinics
  • Specialty Care Centers
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • UCB

Sources

Primary Research Interviews

Industry Stakeholders

• Dermatology consultants and key opinion leaders
• Hospital pharmacy heads
• Biologics manufacturing executives
• Regulatory affairs professionals
• Clinical trial investigators
• Specialty drug distributors

End Users

• Dermatologists in tertiary hospitals
• Rheumatologists in specialty clinics
• Hospital-based immunology departments
• Private dermatology clinic practitioners
• Teaching hospital physicians
• Specialty biologics prescribers

Government and International Databases

• U.S. Food and Drug Administration
• European Medicines Agency
• World Health Organization
• UK Medicines and Healthcare products Regulatory Agency
• Pharmaceuticals and Medical Devices Agency Japan
• OECD Health Statistics

Trade Publications

• Nature Biotechnology
• FierceBiotech
• Pharmaceutical Technology
• BioCentury
• MedTech Insight
• Clinical Trials Arena

Academic Journals

• The Lancet
• Journal of the American Academy of Dermatology
• British Journal of Dermatology
• Annals of the Rheumatic Diseases
• New England Journal of Medicine
• JAMA Dermatology

Reputable Newspapers

• Financial Times
• The Guardian
• The New York Times
• The Wall Street Journal
• The Economist
• Nikkei Asia

Industry Associations

• International Federation of Pharmaceutical Manufacturers and Associations
• European Federation of Pharmaceutical Industries and Associations
• American Academy of Dermatology Association
• European League Against Rheumatism
• International Psoriasis Council
• International Society of Dermatology

Public Domain Resources

• ClinicalTrials.gov
• EU Clinical Trials Register
• WHO Global Health Observatory
• OpenFDA
• National Library of Medicine

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years